Compare Twist Bioscience Corp (TWST) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Union Pacific Corporation — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Union Pacific Corporation trades at $286.67 (market cap $171.36B). The key difference: Union Pacific Corporation is far larger — about 20.4× Twist Bioscience Corp's market cap, and Union Pacific Corporation pays a 1.97% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | UNP | |
|---|---|---|
Market Cap | $8.42B | $171.36B |
Sector | Health | Industrials |
52-Week High | $153.10 | $310.62 |
52-Week Low | $24.16 | $214.91 |
Enterprise Value | $8.35B | $200.42B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Union Pacific (UNP) trades at $288.45, down 0.4% with a bearish technical signal despite strong fundamentals. The company reported solid Q2 2026 earnings beat ($3.41 vs $3.26 expected) and maintains robust profitability with 28.85% net margin and 39.7% ROE. Recent news highlights progress on the Norfolk Southern merger, expected to close by late 2027, while institutional activity shows mixed positioning with some funds increasing stakes while others reduced exposure.
The stock offers upside to the $334.33 consensus price target with 58.7% analyst buy ratings, though technical resistance near $290-294 and merger regulatory risks warrant monitoring. Strong cash flow generation ($9.29B operating cash flow in 2025) and dividend payments ($1.42 declared for H2-26) support shareholder returns, while debt levels remain manageable at 46.06% debt-to-asset ratio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
